Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

Advances in Dual Diagnosis, published by EMERALD GROUP PUBLISHING LTD, serves as a vital resource for professionals and researchers in the fields of psychiatry and mental health. With an ISSN of 1757-0972 and E-ISSN 2042-8324, this journal has been at the forefront of dual diagnosis research since its inception in 2008, aiming to bridge the gap in knowledge and practice regarding the co-occurrence of mental health disorders and substance use issues. Rated in the Q4 category for Psychiatry and Mental Health, it ranks 31st out of 45 in Nursing and Psychiatric Mental Health and 408th out of 567 in Medicine and Psychiatry, providing a unique platform for showcasing emerging research, innovative treatment strategies, and case studies that enhance understanding of complex patient needs. While the journal is not openly accessible, its contributions are crucial for driving forward the academic discourse and practical applications surrounding dual diagnosis. As we look to the future through 2024 and beyond, the Advances in Dual Diagnosis journal continues to strive for excellence in disseminating knowledge that benefits practitioners and scholars alike.

JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.

Sucht-Zeitschrift für Wissenschaft und Praxis, published by HOGREFE AG in Switzerland, is a pivotal journal addressing the interrelated fields of addiction science and mental health. With an ISSN of 0939-5911 and an E-ISSN of 1664-2856, this journal has been dedicated to fostering interdisciplinary research and practical applications since its inception in 1991, continuing through to 2024. As a respected source in the field, it holds a 2023 Q3 quartile ranking in Medicine (miscellaneous), a Q4 ranking in Psychiatry and Mental Health, and a Q3 ranking in Public Health, highlighting its broad relevance and growing impact on contemporary health discussions. While currently not offering open access options, the journal provides a rich platform for researchers, practitioners, and students to share and gain insights into innovative practices and scientific findings that advance the understanding of addiction and its societal implications. With its contributions indexed in Scopus and a variety of rankings reflective of its quality, Sucht-Zeitschrift für Wissenschaft und Praxis serves as an essential resource for those committed to advancing knowledge and practice in addiction-related fields.

Journal of Criminological Research Policy and Practice is a pioneering platform dedicated to the exploration and dissemination of knowledge in the interdisciplinary field of criminology. Published by Emerald Group Publishing Ltd, this journal features high-quality research that addresses contemporary issues and innovative practices in areas such as law, public administration, and social psychology. With an ISSN of 2056-3841 and an E-ISSN of 2056-385X, the journal has garnered a notable presence in the academic community, showcasing a Q3 ranking in Law and Sociology & Political Science as of 2023. The journal provides valuable insights for researchers and practitioners alike, advancing the discourse on criminological policy and its implications for society. It serves as an essential resource for those invested in enhancing social justice, informing policy-making, and understanding the complexities of crime within a broader social context. Encompassing research from 2015 to the present and extending into 2024, the journal stands as a critical reference point for future studies and professional practice in criminology.

Drug and Alcohol Dependence is a premier journal published by Elsevier Ireland Ltd, dedicated to the rigorous exploration and analysis of substance use disorders, including drug and alcohol dependencies. With its established history since 1975 and a remarkable convergence of research extending to 2024, the journal holds a prestigious position within the academic community, evidenced by its Q1 ranking in multiple categories, including Pharmacology, Psychiatry and Mental Health, and Toxicology for 2023. It ranks impressively among its peers, underscored by Scopus rankings of #46, #99, and #27 in key fields related to medical pharmacology and toxicology. As a non-open access title, it caters to a global readership of researchers, professionals, and students, providing them with peer-reviewed insights into critical developments and innovative methodologies in the field. The journal’s commitment to advancing knowledge and understanding of drug and alcohol dependence is essential for addressing the global challenges posed by substance use, making it a valuable resource for all stakeholders in public health and clinical practice.

The Journal of Addictions Nursing, published by Lippincott Williams & Wilkins, serves as a pivotal resource in the field of psychiatric and mental health nursing. With an ISSN of 1088-4602 and an E-ISSN of 1548-7148, this esteemed journal has been dedicated to advancing the knowledge and practice of addiction nursing since its inception in 1989. As of 2023, it ranks in the Q3 category of psychiatry and mental health, highlighting its significance amidst its peers. The journal provides a platform for the dissemination of original research, reviews, and clinical practices that address the complexities of addiction treatment and care. While it currently does not offer open access options, its valuable insights are accessible to practitioners and researchers committed to improving patient outcomes. With content spanning from 1989 to 2024, the journal continues to shape the discourse in this vital area of nursing, making it an essential read for professionals and scholars aiming to stay at the forefront of addiction nursing and intervention strategies.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

SUBSTANCE USE & MISUSE, published by Taylor & Francis Inc, is an esteemed academic journal dedicated to the multifaceted study of substance use and its implications on health and society. With a notable impact factor and categorized in the Q2 quartile across multiple fields—including Health (Social Science), Medicine (Miscellaneous), Psychiatry and Mental Health, as well as Public Health—this journal serves as an essential platform for researchers, professionals, and students alike. Spanning from 1966 to 2024, it provides a rich archive of peer-reviewed articles that explore current trends, innovative research, and evidence-based practices in the management and understanding of substance use. The journal offers various access options, catering to the diverse needs of its audience and affirming its commitment to fostering scholarly discourse in the United Kingdom and beyond. By engaging with this journal, readers can enhance their understanding of the complexities surrounding substance use, making it a crucial resource for advancing knowledge and informing policy in this critical area of public health.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.